{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:02:19Z","timestamp":1773835339883,"version":"3.50.1"},"reference-count":108,"publisher":"Radcliffe Medical Media Ltd","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Refractory angina is a significant clinical problem and its successful management is often extremely challenging. Defined as chronic angina-type chest pain in the presence of myocardial ischaemia that persists despite optimal medical, interventional and surgical treatment, current therapies are limited and new approaches to treatment are needed. With an ageing population and increased survival from coronary artery disease, clinicians will increasingly encounter this complex condition in routine clinical practice. Novel therapies to target myocardial ischaemia in patients with refractory angina are at the forefront of research and in this review we discuss those in clinical translation and assess the evidence behind their efficacy.<\/jats:p>","DOI":"10.15420\/ecr.2018:1:2","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T09:44:41Z","timestamp":1530179081000},"page":"70","source":"Crossref","is-referenced-by-count":17,"title":["New Advances in the Management of Refractory Angina Pectoris"],"prefix":"10.15420","volume":"13","author":[{"given":"Kevin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Specialist Angina Service, Royal Brompton and Harefield NHS Foundation Trust, London, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Imperial College Healthcare NHS Trust, London, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranil de","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Specialist Angina Service, Royal Brompton and Harefield NHS Foundation Trust, London, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Vascular Science Department, National Heart and Lung Institute, London, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina","volume":"23","author":"Mannheimer","year":"2002","unstructured":"1. Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002;23:355-70.","journal-title":"Eur Heart J"},{"key":"ref1","unstructured":"2. Statistics Canada. Canadian Community Health Survey (CCHS). 2002. Available at: www23.statcan.gc.ca\/imdb\/p2SV. pl?Function=getSurvey&Id=3359 (accessed 8 June 2018)"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. McGillion M, Arthur HM, Cook A, et al. Management of patients with refractory angina: Canadian Cardiovascular Society\/Canadian Pain Society joint guidelines. Can J Cardiol 2012;28(2 Suppl):S20-41.","DOI":"10.1016\/j.cjca.2011.07.007"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Povsic TJ, Broderick S, Anstrom KJ, et al. Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc 2015;e001287.","DOI":"10.1161\/JAHA.114.001287"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","unstructured":"5. Henry TD, Satran D, Hodges JS, et al. Long-term survival in patients with refractory angina. Eur Heart J 2013;34:2683-8.","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.15420\/ecr.2016:26:1","article-title":"Management of refractory angina pectoris","volume":"11","author":"Cheng","year":"2016","unstructured":"6. Cheng K, Sainsbury P, Fisher M, et al. Management of refractory angina pectoris. Eur Cardiol Rev 2016;11:69.","journal-title":"Eur Cardiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1136\/heartjnl-2015-308564","article-title":"Alternative interventions for refractory angina","volume":"103","author":"Sainsbury","year":"2017","unstructured":"7. Sainsbury PA, Fisher M, de Silva R. Alternative interventions for refractory angina. Heart 2017;103:1911-22.","journal-title":"Heart"},{"key":"ref7","unstructured":"8. Wright C, de Silva R. Management of refractory angina: the importance of winning over both hearts and minds. Br J Cardiol 2016;23:45-6."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Cheng K, Wright C, de Silva, R. The effect of a multi-disciplinary care pathway for refractory angina on psychological outcomes, quality of life and medication use. European Society of Cardiology Congress 2017, Barcelona, Spain, 1 August 2017. Abstract 2237.","DOI":"10.1093\/eurheartj\/ehx502.2237"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jama.1955.02960300008003","article-title":"Scientific basis for the surgical treatment of coronary artery disease","volume":"159","author":"CS","year":"1955","unstructured":"10. Beck CS, Leighninger DS. Scientific basis for the surgical treatment of coronary artery disease. J Am Med Assoc 1955;159:1264-71.","journal-title":"J Am Med Assoc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jama.1954.02950130006002","article-title":"Operations for coronary artery disease","volume":"156","author":"CS","year":"1954","unstructured":"11. Beck CS, Leighninger DS. Operations for coronary artery disease. J Am Med Assoc 1954;156:1226-33.","journal-title":"J Am Med Assoc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/eurheartj\/ehx486","article-title":"The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives","volume":"39","author":"Konigstein","year":"2017","unstructured":"12. Konigstein M, Giannini F, Banai S. The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives. Eur Heart J 2017;39:925-33.","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"PG","year":"2007","unstructured":"13. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40.","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.jacc.2007.01.061","article-title":"Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study","volume":"49","author":"Banai","year":"2007","unstructured":"14. Banai S, Ben Muvhar S, Parikh KH, et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol 2007;49:1783-9.","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Ormerod JO, Gamble JHP, Betts TR. A device to narrow the coronary sinus for angina. N Engl J Med 2015;372:1966.","DOI":"10.1056\/NEJMc1503672"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1056\/NEJMoa1402556","article-title":"Efficacy of a device to narrow the coronary sinus in refractory angina","volume":"372","author":"Verheye","year":"2015","unstructured":"16. Verheye S, Jolic\u0153ur EM, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med 2015;372:519-27.","journal-title":"N Engl J Med"},{"key":"ref16","unstructured":"17. Cheng K, Wright C, de Silva R. Coronary sinus reducer for the treatment of refractory angina - a single-centre experience. EuroPCR 2017, Paris, France, 16-19 May 2017, Abstract Euro17A-POS0326."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.4244\/EIJV9I10A196","article-title":"Transcatheter treatment for refractory angina with the coronary sinus Reducer","volume":"9","author":"Konigstein","year":"2014","unstructured":"18. Konigstein M, Meyten N, Verheye S, et al. Transcatheter treatment for refractory angina with the coronary sinus Reducer. EuroIntervention 2014;9:1158-64.","journal-title":"EuroIntervention"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.4244\/EIJ-D-17-00626","article-title":"Coronary sinus Reducer non-responders: insights and perspectives","volume":"13","author":"Baldetti","year":"2018","unstructured":"19. Baldetti L, Colombo A, Banai S, et al. Coronary sinus Reducer non-responders: insights and perspectives. EuroIntervention 2018;13:1667-6.","journal-title":"EuroIntervention"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2016.02.018","article-title":"Coronary Sinus Reducer systemTM: A new therapeutic option in refractory angina patients unsuitable for revascularization","volume":"209","author":"Ielasi","year":"2016","unstructured":"20. Ielasi A, Todaro MC, Grigis G, Tespili M. Coronary Sinus Reducer systemTM: A new therapeutic option in refractory angina patients unsuitable for revascularization. Int J Cardiol 2016;209:122-30.","journal-title":"Int J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12471-016-0862-2","article-title":"Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience","volume":"24","author":"Abawi","year":"2016","unstructured":"21. Abawi M, Nijhoff F, Stella PR, et al. Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience. Neth Heart J 2016;24:544-51.","journal-title":"Neth Heart J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jcin.2017.06.062","article-title":"First experience with the coronary sinus reducer system for the management of refractory angina in patients without obstructive coronary artery disease","volume":"10","author":"Giannini","year":"2017","unstructured":"22. Giannini F, Baldetti L, Ielasi A, et al. First experience with the coronary sinus reducer system for the management of refractory angina in patients without obstructive coronary artery disease. JACC Cardiovasc Interv 2017;10:1901-3.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4244\/EIJV6I3A60","article-title":"Contemporary success and complication rates of percutaneous coronary intervention for chronic total coronary occlusions: results from the ALKK quality control registry of 2006","volume":"6","author":"Werner","year":"2010","unstructured":"23. Werner GS, Hochadel M, Zeymer U, et al. Contemporary success and complication rates of percutaneous coronary intervention for chronic total coronary occlusions: results from the ALKK quality control registry of 2006. EuroIntervention 2010;6:361-6.","journal-title":"EuroIntervention"},{"key":"ref23","unstructured":"24. Park S-J. Drug-eluting stent versus optimal medical therapy in patients with coronary chronic total occlusion: DECISION CTO randomized trial. American College of Cardiology Annual Scientific Session 2017, Washington, DC, USA, 18 March 2017. Presentation."},{"key":"ref24","unstructured":"25. Werner GS. A randomized multicentre trial to evaluate the utilization of revascularization or optimal medical therapy for the treatment of chronic total coronary occlusions. EuroPCR 2017, Paris, France, 8 May 2017."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jacc.2007.07.024","article-title":"Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure","volume":"50","author":"Manchanda","year":"2007","unstructured":"26. Manchanda A, Soran O. Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure. J Am Coll Cardiol 2007;50:1523-31.","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0735-1097(03)00329-2","article-title":"Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease","volume":"41","author":"Bonetti","year":"2003","unstructured":"27. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003;41:1761-8.","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1365-2362.2009.02192.x","article-title":"-2 Trial)","volume":"39","author":"Buschmann","year":"2009","unstructured":"28. Buschmann EE, Utz W, Pagonas N, et al. Improvement of fractional flow reserve and collateral flow by treatment with external counterpulsation (Art.Net.-2 Trial). Eur J Clin Invest 2009;39:866-75.","journal-title":"Eur J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/hrt.2009.184507","article-title":"Coronary collateral growth by external counterpulsation: a randomised controlled trial","volume":"96","author":"Gloekler","year":"2010","unstructured":"29. Gloekler S, Meier P, de Marchi SF, et al. Coronary collateral growth by external counterpulsation: a randomised controlled trial. Heart Br Card Soc 2010;96:202-7.","journal-title":"Heart Br Card Soc"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jacc.2006.04.094","article-title":"Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina","volume":"48","author":"Nichols","year":"2006","unstructured":"30. Nichols WW, Estrada JC, Braith RW, et al. Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina. J Am Coll Cardiol 2006;48:1208-14.","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.amjhyper.2006.01.003","article-title":"Cyclic GMP release by acute enhanced external counterpulsation","volume":"19","author":"Levenson","year":"2006","unstructured":"31. Levenson J, Pernollet MG, Iliou MC, et al. Cyclic GMP release by acute enhanced external counterpulsation. Am J Hypertens 2006;19:867-72.","journal-title":"Am J Hypertens"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.109.923482","article-title":"Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study","volume":"122","author":"Braith","year":"2010","unstructured":"32. Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation 2010;122:1612-20.","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.amjcard.2007.08.031","article-title":"Effect of enhanced external counterpulsation on inflammatory cytokines and adhesion molecules in patients with angina pectoris and angiographic coronary artery disease","volume":"101","author":"Casey","year":"2008","unstructured":"33. Casey DP, Conti CR, Nichols WW, et al. Effect of enhanced external counterpulsation on inflammatory cytokines and adhesion molecules in patients with angina pectoris and angiographic coronary artery disease. Am J Cardiol 2008;101:300-2.","journal-title":"Am J Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijcard.2010.08.020","article-title":"Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets","volume":"153","author":"Kiernan","year":"2011","unstructured":"34. Kiernan TJ, Boilson BA, Tesmer L, et al. Effect of enhanced external counterpulsation on circulating CD34+ progenitor cell subsets. Int J Cardiol 2011;153:202-6.","journal-title":"Int J Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.amjcard.2005.07.122","article-title":"Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry)","volume":"97","author":"Soran","year":"2006","unstructured":"35. Soran O, Kennard ED, Kfoury AG, Kelsey SF. IEPR Investigators. Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry). Am J Cardiol 2006;97:17-20.","journal-title":"Am J Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/clc.20117","article-title":"Enhanced external counterpulsation in the treatment of chronic refractory angina: a long-term follow-up outcome from the International Enhanced External Counterpulsation Patient Registry","volume":"31","author":"Loh","year":"2008","unstructured":"36. Loh PH, Cleland JGF, Louis AA, et al. Enhanced external counterpulsation in the treatment of chronic refractory angina: a long-term follow-up outcome from the International Enhanced External Counterpulsation Patient Registry. Clin Cardiol 2008;31:159-64.","journal-title":"Clin Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0735-1097(99)00140-0","article-title":"The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes","volume":"33","author":"Arora","year":"1999","unstructured":"37. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999;33:1833-40.","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1592\/phco.30.7.639","article-title":"Impact of enhanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis","volume":"30","author":"Shah","year":"2010","unstructured":"38. Shah SA, Shapiro RJ, Mehta R, Snyder JA. Impact of enhanced external counterpulsation on Canadian Cardiovascular Society angina class in patients with chronic stable angina: a meta-analysis. Pharmacotherapy 2010;30: 639-45.","journal-title":"Pharmacotherapy"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Zhang C, Liu X, Wang X, et al. Efficacy of enhanced external counterpulsation in patients with chronic refractory angina on Canadian Cardiovascular Society (CCS) angina class: An updated meta-analysis. Medicine (Baltimore) 2015;94:e2002.","DOI":"10.1097\/MD.0000000000002002"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13240","article-title":"Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis","volume":"13","author":"McKenna","year":"2009","unstructured":"40. McKenna C, McDaid C, Suekarran S, et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health Technol Assess 2009;13:1-90.","journal-title":"Health Technol Assess"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Amin F, Al Hajeri A, Civelek B, et al. Enhanced external counterpulsation for chronic angina pectoris. Cochrane Database Syst Rev 2010;(2):CD007219.","DOI":"10.1002\/14651858.CD007219.pub2"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Force Members","year":"2013","unstructured":"42. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.","journal-title":"Eur Heart J"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIR.0000000000000095","article-title":"2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"130","author":"Fihn","year":"2014","unstructured":"43. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014;130:1749-67.","journal-title":"Circulation"},{"key":"ref43","unstructured":"44. Roberts, R. Correspondence: is it time for a re-assessment of EECP in the UK? Br J Cardiol 2014;21:51."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/clc.22395","article-title":"Enhanced external counterpulsation is cost-effective in reducing hospital costs in refractory angina patients","volume":"38","author":"Lawson","year":"2015","unstructured":"45. Lawson WE, Hui JCK, Kennard ED, Linnemeier G. IEPR-II Investigators. Enhanced external counterpulsation is cost-effective in reducing hospital costs in refractory angina patients. Clin Cardiol 2015;38:344-9.","journal-title":"Clin Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.carrev.2014.10.011","article-title":"The beneficial effect of extracorporeal shockwave myocardial revascularization in patients with refractory angina","volume":"16","author":"Alunni","year":"2015","unstructured":"46. Alunni G, Marra S, Meynet I, et al. The beneficial effect of extracorporeal shockwave myocardial revascularization in patients with refractory angina. Cardiovasc Revascularization Med 2015;16:6-11.","journal-title":"Cardiovasc Revascularization Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MCA.0000000000000218","article-title":"Extracorporeal shockwave myocardial therapy is efficacious in improving symptoms in patients with refractory angina pectoris - a multicenter study","volume":"26","author":"Prasad","year":"2015","unstructured":"47. Prasad M, Wan Ahmad WA, Sukmawan R, et al. Extracorporeal shockwave myocardial therapy is efficacious in improving symptoms in patients with refractory angina pectoris - a multicenter study. Coron Artery Dis 2015;26:194-200.","journal-title":"Coron Artery Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijcard.2015.05.067","article-title":"Extracorporeal shockwave myocardial revascularization therapy in refractory angina patients","volume":"194","author":"Slavich","year":"2015","unstructured":"48. Slavich M, Ancona F, Margonato A. Extracorporeal shockwave myocardial revascularization therapy in refractory angina patients. Int J Cardiol 2015;194:93.","journal-title":"Int J Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00019501-200602000-00011","article-title":"Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease","volume":"17","author":"Fukumoto","year":"2006","unstructured":"49. Fukumoto Y, Ito A, Uwatoku T, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 2006;17:63-70.","journal-title":"Coron Artery Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1161\/01.CIR.0000148849.51177.97","article-title":"Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo","volume":"110","author":"Nishida","year":"2004","unstructured":"50. Nishida T, Shimokawa H, Oi K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 2004;110:3055-61.","journal-title":"Circulation"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1620\/tjem.214.151","article-title":"Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits","volume":"214","author":"Oi","year":"2008","unstructured":"51. Oi K, Fukumoto Y, Ito K, et al. Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits. Tohoku J Exp Med 2008;214:151-8.","journal-title":"Tohoku J Exp Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1161\/CIRCULATIONAHA.106.628623","article-title":"Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia","volume":"114","author":"Aicher","year":"2006","unstructured":"52. Aicher A, Heeschen C, Sasaki K, et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 2006;114:2823-30.","journal-title":"Circulation"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1001\/jama.2013.3527","article-title":"Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial","volume":"309","author":"Assmus","year":"2013","unstructured":"53. Assmus B, Walter DH, Seeger FH, et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013;309:1622-31.","journal-title":"JAMA"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12947-017-0102-y","article-title":"Cardiac shock-wave therapy in the treatment of coronary artery disease: systematic review and meta-analysis","volume":"15","author":"Burneikaite\u00b7","year":"2017","unstructured":"54. Burneikaite\u00b7 G, Shkolnik E, C\u02c7 elutkiene\u00b7 J, et al. Cardiac shock-wave therapy in the treatment of coronary artery disease: systematic review and meta-analysis. Cardiovasc Ultrasound 2017;15:11.","journal-title":"Cardiovasc Ultrasound"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"55. Ping Y, Yun-zhu P, Tao G, et al. A clinical study of the extracorporeal cardiac shock wave therapy for coronary artery disease. Heart 2012;98(Suppl 2):E163-4.","DOI":"10.1136\/heartjnl-2012-302920j.14"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.carrev.2017.05.006","article-title":"The beneficial effect of extracorporeal shockwave myocardial revascularization: Two years of follow-up","volume":"18","author":"Alunni","year":"2017","unstructured":"56. Alunni G, Barbero U, Vairo A, et al. The beneficial effect of extracorporeal shockwave myocardial revascularization: Two years of follow-up. Cardiovasc Revasc Med 2017;18:572-6.","journal-title":"Cardiovasc Revasc Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease - addenda","volume":"34","author":"57","year":"2013","unstructured":"57. 2013 ESC guidelines on the management of stable coronary artery disease - addenda. Eur Heart J 2013;34:2949-3003.","journal-title":"Eur Heart J"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa055706","article-title":"Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction","volume":"355","author":"Lunde","year":"2006","unstructured":"58. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-209.","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0140-6736(05)67861-0","article-title":"Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial","volume":"367","author":"Janssens","year":"2006","unstructured":"59. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006;367:113-21.","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2012.418","article-title":"Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial","volume":"307","author":"Perin","year":"2012","unstructured":"60. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012;307:1717-26.","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.carrev.2009.04.001","article-title":"Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency","volume":"11","author":"Flores-Ram\u00edrez","year":"2010","unstructured":"61. Flores-Ram\u00edrez R, Uribe-Longoria A, Rangel-Fuentes MM, et al. Intracoronary infusion of CD133+ endothelial progenitor cells improves heart function and quality of life in patients with chronic post-infarct heart insufficiency. Cardiovasc Revascularization Med 2010;11:72-8.","journal-title":"Cardiovasc Revascularization Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ahj.2014.03.022","article-title":"Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial","volume":"168","author":"Perin","year":"2014","unstructured":"62. Perin EC, Sanz-Ruiz R, S\u00e1nchez PL, et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J 2014;168:88-95.","journal-title":"Am Heart J"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/eurheartj\/ehu192","article-title":"Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience","volume":"36","author":"Menasch\u00e9","year":"2015","unstructured":"63. Menasch\u00e9 P, Vanneaux V, Fabreguettes JR, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J 2015;36:743-50.","journal-title":"Eur Heart J"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/eurheartj\/ehv189","article-title":"Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report","volume":"36","author":"Menasch\u00e9","year":"2015","unstructured":"64. Menasch\u00e9 P, Vanneaux V, Hag\u00e8ge A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J 2015;36:2011-7.","journal-title":"Eur Heart J"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012;126(11 Suppl 1):S29-37.","DOI":"10.1161\/CIRCULATIONAHA.111.084343"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0092-8674(03)00687-1","article-title":"Adult cardiac stem cells are multipotent and support myocardial regeneration","volume":"114","author":"Beltrami","year":"2003","unstructured":"66. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-76.","journal-title":"Cell"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1161\/CIRCULATIONAHA.109.909093","article-title":"Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts","volume":"121","author":"M-M","year":"2010","unstructured":"67. Zaruba M-M, Soonpaa M, Reuter S, Field LJ. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 2010;121:1992-2000.","journal-title":"Circulation"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13309","article-title":"c-kit+ cells minimally contribute cardiomyocytes to the heart","volume":"509","author":"van Berlo","year":"2014","unstructured":"68. van Berlo JH, Kanisicak O, Maillet M, et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014;509:337-41.","journal-title":"Nature"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(11)61590-0","article-title":"Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial","volume":"378","author":"Bolli","year":"2011","unstructured":"69. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378: 1847-57.","journal-title":"Lancet"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(12)60195-0","article-title":"Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial","volume":"379","author":"Makkar","year":"2012","unstructured":"70. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379:895-904.","journal-title":"Lancet"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jacc.2013.08.724","article-title":"Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction)","volume":"63","author":"Malliaras","year":"2014","unstructured":"71. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014;63:110-22.","journal-title":"J Am Coll Cardiol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/CIRCRESAHA.116.304671","article-title":"Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial","volume":"116","author":"Ishigami","year":"2015","unstructured":"72. Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 2015;116:653-64.","journal-title":"Circ Res"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/eurheartj\/ehw113","article-title":"Position paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure","volume":"37","author":"Madonna","year":"2016","unstructured":"73. Madonna R, Van Laake LW, Davidson SM, et al. Position paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J 2016;37:1789-98.","journal-title":"Eur Heart J"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1093\/eurheartj\/ehx248","article-title":"Global position paper on cardiovascular regenerative medicine","volume":"38","author":"Fern\u00e1ndez-Avil\u00e9s","year":"2017","unstructured":"74. Fern\u00e1ndez-Avil\u00e9s F, Sanz-Ruiz R, Climent AM, et al. Global position paper on cardiovascular regenerative medicine. Eur Heart J 2017;38:2532-46.","journal-title":"Eur Heart J"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ahj.2011.01.028","article-title":"A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)","volume":"161","author":"Perin","year":"2011","unstructured":"75. Perin EC, Silva GV, Henry TD, et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011;161:1078-87.","journal-title":"Am Heart J"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1093\/eurheartj\/ehm485","article-title":"Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial)","volume":"28","author":"Tse","year":"2007","unstructured":"76. Tse HF, Thambar S, Kwong YL, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007;28:2998-3005.","journal-title":"Eur Heart J"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2009.685","article-title":"Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial","volume":"301","author":"van Ramshorst","year":"2009","unstructured":"77. van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009;301:1997-2004.","journal-title":"JAMA"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3727\/096368909X484671","article-title":"Refractory angina cell therapy (ReACT) involving autologous bone marrow cells in patients without left ventricular dysfunction: a possible role for monocytes","volume":"18","author":"Hossne","year":"2009","unstructured":"78. Hossne NA, Invitti AL, Buffolo E, et al. Refractory angina cell therapy (ReACT) involving autologous bone marrow cells in patients without left ventricular dysfunction: a possible role for monocytes. Cell Transplant 2009;18:1299-310.","journal-title":"Cell Transplant"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1479-5876-9-183","article-title":"Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina","volume":"9","author":"Tuma","year":"2011","unstructured":"79. Tuma J, Fern\u00e1ndez-Vi\u00f1a R, Carrasco A, et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med 2011;9:183.","journal-title":"J Transl Med"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"80. Mann I, Rodrigo SF, van Ramshorst J, et al. Repeated intramyocardial bone marrow cell injection in previously responding patients with refractory angina again improves myocardial perfusion, anginal complaints, and quality of life. Circ Cardiovasc Interv 2015;8:e002740.","DOI":"10.1161\/CIRCINTERVENTIONS.115.002740"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3727\/096368914X681595","article-title":"Long-term and sustained therapeutic results of a specific promonocyte cell formulation in refractory angina: ReACT\u00ae (Refractory Angina Cell Therapy) clinical update and cost-effective analysis","volume":"24","author":"Hossne","year":"2015","unstructured":"81. Hossne NA, Cruz E, Buffolo E, et al. Long-term and sustained therapeutic results of a specific promonocyte cell formulation in refractory angina: ReACT\u00ae (Refractory Angina Cell Therapy) clinical update and cost-effective analysis. Cell Transplant 2015;24:955-70.","journal-title":"Cell Transplant"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3727\/096368912X636830","article-title":"Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up","volume":"22","author":"Haack-S\u00f8rensen","year":"2013","unstructured":"82. Haack-S\u00f8rensen M, Friis T, Mathiasen AB, et al. Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up. Cell Transplant 2013;22:521-8.","journal-title":"Cell Transplant"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijcard.2013.10.079","article-title":"Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina - final 3-year follow-up","volume":"170","author":"Mathiasen","year":"2013","unstructured":"83. Mathiasen AB, Haack-S\u00f8rensen M, J\u00f8rgensen E, Kastrup J. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina - final 3-year follow-up. Int J Cardiol 2013;170:246-51.","journal-title":"Int J Cardiol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1161\/CIRCULATIONAHA.106.687376","article-title":"Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial","volume":"115","author":"Losordo","year":"2007","unstructured":"84. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I\/IIa double-blind, randomized controlled trial. Circulation 2007;115:3165-72.","journal-title":"Circulation"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000320217","article-title":"Intracoronary autologous CD34+ stem cell therapy for intractable angina","volume":"117","author":"Wang","year":"2010","unstructured":"85. Wang S, Cui J, Peng W, et al. Intracoronary autologous CD34+ stem cell therapy for intractable angina. Cardiology 2010;117:140-7.","journal-title":"Cardiology"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","unstructured":"86. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011;109:428-36.","journal-title":"Circ Res"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW Trial: efficacy and safety of intramyocardial autologous CD34(+) cell administration in patients with refractory angina","volume":"9","author":"Povsic","year":"2016","unstructured":"87. Povsic TJ, Henry TD, Traverse JH et al. The RENEW Trial: efficacy and safety of intramyocardial autologous CD34(+) cell administration in patients with refractory angina. JACC Cardiovasc Interv 2016;9:1576-85.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3727\/096368916X691484","article-title":"Autologous CD34(+) cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study","volume":"25","author":"Henry","year":"2016","unstructured":"88. Henry TD, Schaer GL, Traverse JH, et al. Autologous CD34(+) cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant 2016;25:1701-11.","journal-title":"Cell Transplant"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-2007-989351","article-title":"Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results","volume":"56","author":"Pompilio","year":"2008","unstructured":"89. Pompilio G, Steinhoff G, Liebold A, et al. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results. Thorac Cardiovasc Surg 2008;56:71-6.","journal-title":"Thorac Cardiovasc Surg"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/CIRCRESAHA.115.303463","article-title":"Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial","volume":"115","author":"Jimenez-Quevedo","year":"2014","unstructured":"90. Jimenez-Quevedo P, Gonzalez-Ferrer JJ, Sabate M, et al. Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial. Circ Res 2014;115:950-60.","journal-title":"Circ Res"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCRESAHA.116.309009","article-title":"Effects of transendocardial delivery of bone marrow-derived CD133(+) cells on left ventricle perfusion and function in patients with refractory angina: final results of randomized, double-blinded, placebo-controlled REGENT-VSEL trial","volume":"120","author":"Wojakowski","year":"2017","unstructured":"91. Wojakowski W, Jadczyk T, Michalewska-W\u0142udarczyk A, et al. Effects of transendocardial delivery of bone marrow-derived CD133(+) cells on left ventricle perfusion and function in patients with refractory angina: final results of randomized, double-blinded, placebo-controlled REGENT-VSEL trial. Circ Res 2017;120:670-80.","journal-title":"Circ Res"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/ccd.26601","article-title":"The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction","volume":"89","author":"Henry","year":"2017","unstructured":"92. Henry TD, Pepine CJ, Lambert CR, et al. The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv 2017;89:169-77.","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1161\/CIRCULATIONAHA.105.541268","article-title":"Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction","volume":"113","author":"Iwasaki","year":"2006","unstructured":"93. Iwasaki H. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006;113:1311-25.","journal-title":"Circulation"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12265-010-9248-9","article-title":"Resident vascular progenitor cells-diverse origins, phenotype, and function","volume":"4","author":"Psaltis","year":"2011","unstructured":"94. Psaltis PJ, Harbuzariu A, Delacroix S, et al. Resident vascular progenitor cells-diverse origins, phenotype, and function. J Cardiovasc Transl Res 2011;4:161-76.","journal-title":"J Cardiovasc Transl Res"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"95. Povsic TJ, Junge C, Nada A, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J 2013;165:854-61.e2.","DOI":"10.1016\/j.ahj.2013.03.003"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-2007-989351","article-title":"Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results","volume":"56","author":"Pompilio","year":"2008","unstructured":"96. Pompilio G, Steinhoff G, Liebold A, et al. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results. Thorac Cardiovasc Surg 2008;56:71-6.","journal-title":"Thorac Cardiovasc Surg"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/CIRCRESAHA.115.303463","article-title":"Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial","volume":"115","author":"Jimenez-Quevedo","year":"2014","unstructured":"97. Jimenez-Quevedo P, Gonzalez-Ferrer JJ, Sabate M, et al. Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial. Circ Res 2014;115:950-60.","journal-title":"Circ Res"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cjca.2012.12.003","article-title":"Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials","volume":"29","author":"Li","year":"2013","unstructured":"98. Li N, Yang Y-J, Zhang Q, et al. Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials. Can J Cardiol 2013;29:908-14.","journal-title":"Can J Cardiol"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"99. Fisher SA, Dor\u00e9e C, Brunskill SJ, et al. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PloS One 2013;8:e64669.","DOI":"10.1371\/journal.pone.0064669"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCRESAHA.115.308056","article-title":"Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis","volume":"118","author":"Khan","year":"2016","unstructured":"100. Khan AR, Farid TA, Pathan A, et al. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis. Circ Res 2016;118: 984-93.","journal-title":"Circ Res"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"101. Martin-Rendon E. Meta-analyses of human cell-based cardiac regeneration therapies: What can systematic reviews tell us about cell therapies for ischemic heart disease? Circ Res 2016;118:1264-72.","DOI":"10.1161\/CIRCRESAHA.115.307540"},{"key":"ref101","unstructured":"102. Gy\u00f6ngy\u00f6si, M. ACCRUE and cell-based therapy meta-analysis. European Society of Cardiology Congress 2017, Barcelona, Spain, 1 August 2017. Abstract 988 [Oral Presentation]."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.116.304346","article-title":"Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data","volume":"116","author":"Gy\u00f6ngy\u00f6si","year":"2015","unstructured":"103. Gy\u00f6ngy\u00f6si M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015;116:1346-60.","journal-title":"Circ Res"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.115.307347","article-title":"Meta-analyses of human cell-based cardiac regeneration therapies: Controversies in meta-analyses results on cardiac cell-based regenerative studies","volume":"118","author":"Gy\u00f6ngy\u00f6si","year":"2016","unstructured":"104. Gy\u00f6ngy\u00f6si M, Wojakowski W, Navarese EP, et al. Meta-analyses of human cell-based cardiac regeneration therapies: Controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res 2016;118:1254-63.","journal-title":"Circ Res"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"105. Henry TD, Losordo DW, Traverse JH, et al. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J 2018.","DOI":"10.1093\/eurheartj\/ehx764"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"106. Henry TD, Povsic TJ. Repeat cell therapy for refractory angina: D\u00e9j\u00e0 vu all over again? Circ Cardiovasc Interv 2015;8:e003049.","DOI":"10.1161\/CIRCINTERVENTIONS.115.003049"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/heart.89.8.830","article-title":"Enhanced external counterpulsation for refractory angina pectoris","volume":"89","author":"Sinvhal","year":"2003","unstructured":"107. Sinvhal RM, Gowda RM, Khan IA. Enhanced external counterpulsation for refractory angina pectoris. Heart 2003;89:830-3.","journal-title":"Heart"},{"key":"ref107","unstructured":"108. ECP Machine (External CounterPulsation). Yati Mediquip. 2018. Available at: www.yatimediquip.com\/what-is-ecp.html (accessed 10 April 2018)."}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articles\/new-advances-management-refractory-angina-pectoris","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T08:51:18Z","timestamp":1599641478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articles\/new-advances-management-refractory-angina-pectoris"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["ecr.2018:1:2"],"URL":"https:\/\/doi.org\/10.15420\/ecr.2018:1:2","relation":{},"ISSN":["1758-3756"],"issn-type":[{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}